What is the recommended starting dose, titration, and monitoring for lisinopril in a male patient with mild hepatic impairment?

Lisinopril Dosing in Mild Hepatic Impairment

No dose adjustment is required for lisinopril in patients with mild hepatic impairment (Child-Pugh A). Start with the standard dose of 10 mg once daily for hypertension, 5 mg once daily for heart failure, or 5 mg for acute MI, and titrate based on blood pressure response and tolerability 1.

Rationale

The FDA labeling for lisinopril explicitly addresses renal impairment but makes no mention of hepatic impairment requiring dose adjustment 1. This is because lisinopril is unique among ACE inhibitors—it is not metabolized by the liver and is excreted unchanged in the urine 2. Unlike enalapril (which requires hepatic conversion to its active form), lisinopril is already in its active form and does not undergo hepatic biotransformation.

The 2021 ACC guideline 3 discusses hepatic impairment dosing for sacubitril/valsartan (an ARNI), noting that mild hepatic impairment (Child-Pugh A) requires no starting dose adjustment. While this guideline doesn't specifically address lisinopril, it reinforces that mild hepatic impairment typically doesn't necessitate dose modifications for cardiovascular medications unless they undergo significant hepatic metabolism.

Starting Doses by Indication

For Hypertension:

• Standard starting dose: 10 mg once daily 1
• If already on diuretics: 5 mg once daily 1
• Titrate to 20-40 mg daily based on BP response (maximum studied: 80 mg, though no additional benefit typically seen) 1

For Heart Failure:

• Standard starting dose: 5 mg once daily 1
• If hyponatremic (Na <130 mEq/L): 2.5 mg once daily 1
• Titrate to maximum of 40 mg daily as tolerated 1

For Acute MI:

• 5 mg within 24 hours, then 5 mg at 24 hours, 10 mg at 48 hours, then 10 mg daily 1
• If low BP (≤120 mmHg): start with 2.5 mg 1

Monitoring Parameters

Monitor the following at baseline, 1-2 weeks after initiation, and after each dose increase:

• Blood pressure (sitting and standing to assess for hypotension)
• Serum creatinine and eGFR (lisinopril is renally excreted; watch for acute kidney injury)
• Serum potassium (risk of hyperkalemia, especially with concurrent diuretics or renal impairment)
• Liver enzymes (ALT, AST, alkaline phosphatase) at baseline and if symptoms develop

Critical Caveats

Hepatotoxicity Risk: While lisinopril doesn't require hepatic dose adjustment, rare cases of drug-induced liver injury (DILI) have been reported, presenting as either hepatocellular or cholestatic patterns 4, 5. One case showed fulminant hepatic cholestasis occurring 8 weeks after initiation 5, and another presented with cholestatic jaundice 27 months after starting 4. If jaundice, significant transaminase elevation, or cholestasis develops, discontinue lisinopril immediately as continued use risks fulminant hepatic failure 5.

Renal Function Takes Priority: Since lisinopril is renally eliminated, any concurrent renal impairment (common in patients with hepatic disease) requires dose adjustment 1:

• CrCl >30 mL/min: no adjustment needed
• CrCl 10-30 mL/min: reduce initial dose by 50% (e.g., 5 mg for hypertension)
• CrCl <10 mL/min or hemodialysis: start with 2.5 mg once daily

Avoid Hypotension: Patients with hepatic impairment may have altered hemodynamics. Start conservatively if there's any concern about volume status or if systolic BP is <120 mmHg 1.

Titration Strategy

• Increase dose every 2-4 weeks based on BP response and tolerability
• Target BP <130/80 mmHg for most patients
• If BP not controlled on lisinopril alone, add low-dose hydrochlorothiazide (12.5 mg) rather than pushing lisinopril to maximum dose 1
• Maximum dose: 40 mg daily (doses up to 80 mg studied but show no additional benefit) 1